T1	Participants 410 503	pancreatic cancer patients treated with adjuvant gemcitabine compared with untreated patients
T2	Participants 645 827	Tissue samples of 162 patients were available for immunohistochemistry on tissue microarrays to evaluate the impact of Î±-SMA expression and stromal density impact on patient outcome.
